OncoSec Medical Inc IPO-Jahr
Was ist das IPO-Jahr von OncoSec Medical Inc?
IPO-Jahr von OncoSec Medical Inc ist 2011
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu OncoSec Medical Inc
Was macht OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Unternehmen mit ipo-jahr ähnlich OncoSec Medical Inc
- Goldman Sachs Mutual Fund - Goldman Sachs Nifty Exchange Traded Scheme hat IPO-Jahr von 2010
- Software Effective Solutions hat IPO-Jahr von 2010
- GINSMS hat IPO-Jahr von 2010
- Photonike Capital SA hat IPO-Jahr von 2010
- Parabolic Drugs hat IPO-Jahr von 2010
- West Kirkland Mining hat IPO-Jahr von 2010
- OncoSec Medical Inc hat IPO-Jahr von 2011
- Omineca Mining and Metals hat IPO-Jahr von 2012
- iShares Asia Trust - iShares Core CSI 300 Index ETF hat IPO-Jahr von 2012
- Wendy`s Co hat IPO-Jahr von 2012
- Unisys hat IPO-Jahr von 2012
- Christopher & Banks hat IPO-Jahr von 2012
- Wellesley hat IPO-Jahr von 2012